Orbimed Advisors LLC Curis Inc Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.31 - $5.13 $8.4 Million - $18.6 Million	-3,634,800 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $504,630 - $917,406	113,400 Added 3.22%	3,634,800 $17.3 Million
Q2 2021 Aug 16, 2021	SELL	$7.45 - $16.27 $6.3 Million - $13.7 Million	-845,094 Reduced 19.35%	3,521,400 $28.4 Million
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $3.38 Million - $25.6 Million	3,125,000 Added 251.71%	4,366,494 $35.8 Million
Q2 2020 Aug 14, 2020	SELL	$0.63 - $1.7 $73,627 - $198,677	-116,869 Reduced 8.6%	1,241,494 $1.5 Million
Q4 2019 Feb 14, 2020	BUY	$1.36 - $2.44 $158,941 - $285,160	116,869 Added 9.41%	1,358,363 $2.31 Million
Q3 2019 Nov 14, 2019	BUY	$1.74 - $2.83 $2.16 Million - $3.51 Million	1,241,494 New	1,241,494 $2.78 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.